Adrenocortical carcinoma is a rare tumor with a poor prognosis. The clinical features and rational bases of pharmacologic therapy of adrenocortical carcinoma are discussed in the light of the case of a patient with a bulky, inoperable tumor whose treatment with mitotane was followed by a dramatic regression though several, important side effects.